P11-4 Efficacy and safety of anti-CD38 antibodies in combination with pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

Incorporating anti-CD38 antibodies into novel agents has shown to improve survival and response in patients with multiple myeloma (MM). However, the efficacy and safety of anti-CD38 antibodies in combination with pomalidomide plus dexamethasone in patients with relapsed/refractory MM (RRMM) remains unknown in a real-world setting. We present the efficacy and safety of these regimens in 5 patients with RRMM.